Brain 17 Vienna

Alectinib vs Crizotinib trial

ALK+ advanced NSCLC

randomise

alectinib

crizotinib

152 patients

151 patients

Brain metastases in patients with ALK-positive NSCLC

Peters et al 2017, N Engl J Med; 377: 829-38